|
GB0907255D0
|
|
Use of variant interferon alpha
|
|
GB0821979D0
|
|
Use of variant interferon alpha
|
|
GB0808423D0
|
|
Use of varient interferon alpha
|
|
CN101528266A
|
|
Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1
|
|
AU2007296843A1
|
|
Polymer conjugates of Box-A of HMGB1 and Box-A variants of HMGB1
|
|
BRPI0615277A2
|
|
k-252a polymer conjugate, pharmaceutical composition comprising said conjugate as well as use thereof
|
|
CN101248105A
|
|
Polymer conjugates of K-252a and derivatives thereof
|
|
EP1797118A2
|
|
Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use
|
|
BRPI0512944A
|
|
therapeutic agents for the treatment of hmgb1-related conditions
|
|
MX2007001155A
|
|
Methods, systems, and computer program products for providing presence gateway functionality in a telecommunications network.
|
|
CA2497890A1
|
|
A mechanism for hiv-1 entry into host cells and peptides inhibiting this mechanism
|
